5689-83-8

Basic information

• Product Name: PROPANE 1,2-CYCLIC SULFATE
• Synonyms: PROPANE 1,2-CYCLIC SULFATE;4-METHYL-1,3,2-DIOXATHIOLANE-2,2-DIOXIDE;1,2-Propanediol cyclic sulfate;4-Methyl-2,2-dioxo-1,3,2-dioxathiolane;Propylene sulfate;1,3,2-Dioxathiolane,4-methyl-, 2,2-dioxide
• CAS NO: 5689-83-8
• Molecular Formula: C₃H₆O₄S
• Molecular Weight: 138.14
• Product Categories: Fine Chemical
• Mol File: 5689-83-8.mol
• Article Data: 13

Chemical Properties

• Melting Point: 57-58 °C
• Boiling Point: 50°C/0.1mmHg(lit.)
• Flash Point: >110℃
• Appearance: /
• Density: 1.408 g/mL
• Refractive Index: n/D1.419
• CAS DataBase Reference: PROPANE 1,2-CYCLIC SULFATE(CAS DataBase Reference)
• NIST Chemistry Reference: PROPANE 1,2-CYCLIC SULFATE(5689-83-8)
• EPA Substance Registry System: PROPANE 1,2-CYCLIC SULFATE(5689-83-8)

Safety Data

• Hazardous Substances Data: 5689-83-8(Hazardous Substances Data)

Usage

Uses

4-Methyl-2,2-dioxo-1,3,2-dioxathiolane, can be used in the synthesis of stereoisomers of Secnidazole (S225000), which is a nitroimidazole anti-infective, that is shown to be effective in treatment of dientamoebiasis, and Atopobium vaginae.

Upstream product

• 57-55-6 propylene glycol 
• 558-30-5 2-methyl-1,2-epoxypropane 
• 1469-73-4 4-methyl-2-oxo-1,3,2-dioxathiolane 

Downstream Products

• 124536-03-4 C₉H₁₁O₅S^(1-)*K⁽¹⁺⁾ 
• 430-50-2 1-fluoropropan-2-ol 
• 3824-87-1 2-fluoro-1-hydroxypropane 
• 144175-17-7 (E)-α-(Tetrahydro-5-methyl-2-furylidene)acetone 
• 99206-61-8 (+/-)-hex-4-yn-2-ol 
• 101054-93-7 4,4,4-trifluoro-2-butanol 
• 16330-23-7 1-phenyl-1-pentyn-4-ol 
• 431-23-2 (S*)-3,3,3-trifluoro-2-methylpropan-1-ol 

Relevant articles and documents

Preparation method of cyclic sulfate

The invention discloses a preparation method of cyclic sulfate, which is used for preparing cyclic sulfate by a one-step method, and has the beneficial effects that an epoxy compound is used as a rawmaterial to react with sulfamic acid or sulfuric acid in one step under the participation of anhydride to prepare cyclic sulfate, and noble metal catalysis is not needed in the preparation process; corrosive gas production is achieved, the product is high in purity and low in chromaticity (less than 20Hazen), the moisture content is less than or equal to 20ppm, and the acid value is less than or equal to 10ppm, and the influence of moisture and acid value in the electrolyte on the cycle performance and storage stability of the battery is effectively changed.

A method for preparing [...] (by machine translation)

The invention relates to a method for preparing [...], comprising the following steps: S1. The nucleophilic substitution reaction: to propylene glycol and thionyl chloride as the starting material, chloroform as solvent, the nucleophilic substitution reaction, by the sulfurous acid propylene chloroform solution; S2. Oxidation reaction: high iodic acid as the oxidizing agent, the ruthenium trichloride hydrate catalyst, to S1 to obtain solution in the oxidation process is performed on the sulfurous acid propylene shall [...]; S3. The refined purification: sulfuric acid propylene crude soluble in chloroform, under the protection of nitrogen, heating to reflux is fully dissolved, then lower the temperature crystallization, filtering, filters the cake to pass through reduced-pressure drying, to obtain. The mild reaction conditions of the present invention, the synthetic process is simple, easy to operate, high safety, preparation cycle is short, the raw materials used are simple and easy to obtain, the cost is low, few by-products, the preparation of the product has high purity, low water content, low acid value of the product, the product yield is high, and is suitable for industrial production. (by machine translation)

Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups

Blood borne hepatitis C infections are the primary cause for liver cirrhosis and hepatocellular carcinoma. HCV NS3 protease, a pivotal enzyme in the replication cycle of HCV virus has been the primary target for development of new drug candidates. Boceprevir and telaprevir are two novel ketoamide derived inhibitors that are currently undergoing phase-III clinical trials. These inhibitors include ketoamide functionality as serine trap and have an acidic alpha-ketoamide center that undergoes epimerization under physiological conditions. Our initial attempts to arrest this epimerization by introducing quaternary amino acids at P1 had resulted in significantly diminished activity. In this manuscript we describe alpha quaternized P1 group that result in potent inhibitors in the enzyme assay and demonstrate cellular activity comparable to boceprevir.